Rising Number of People with Vision Impairment Catalyzing the Global Ocular Drug Delivery Mode Market Growth

The Global Ocular Drug Delivery Mode market is projected to grow at an astronomical rate in the forecast years. The market growth is attributed to growing geriatric population, increasing number of people with vision impairment, and rising prevalence of eye disorders such as diabetic retinopathy, trachoma, and corneal opacities in the people usually at the ages of 50 or above. Moreover, the extensive R&D activities to develop innovative products, rising ophthalmic surgeries, and launch of ocular products by the market players are some of the factors driving the growth of the ocular drug delivery mode market.

According to MarkNtel Advisors’ research report “Global Ocular Drug Delivery Mode Market Analysis, 2020”, the Global Ocular Drug Delivery Mode market is anticipated to grow at a CAGR of around 7.5% during 2020-25. Based on Disease Type, Cataract acquired a considerable market share in the Global Ocular Drug Delivery Mode market in 2019. Among the low- and middle-income countries of Africa and South Asia, the incidences of congenital cataract cases are higher among the people especially among women, mostly due to the lack of ophthalmic clinics and adequate government services activities.

View Report: https://www.marknteladvisors.com/research-library/global-ocular-drug-delivery-mode-market.html?utm_source=Openpr&utm_medium=PR

“Global Ocular Drug Delivery Mode Market Analysis, 2020” provides comprehensive qualitative and quantitative insights on the industry potential, key factors impacting sales and purchase decisions, hotspots, and growth opportunities available for Ocular Drug Delivery Mode providers across the globe. Moreover, the report also encompasses the key strategic imperatives for success for competitors along with strategic factorial indexing measuring competitor's capabilities on 16 parameters. This will help companies in the formulation of Go to Market Strategies and identifying the blue ocean for its offerings.

North America Acquired the Majority Market Share
North America acquired the majority market share in 2019. US acquired the largest share in the North America market. This is due to the growing awareness among the people about ocular products, increasing prevalence of diabetic retinopathy among adults 40 years and older in the United States, and high cost of cataract surgeries. Around 300,000 cataract surgeries are performed in USA every year. The cost of the surgeries in US goes around USD 5400 which commonly costs less in comparison with UK 3760USD and Europe 950USD, hence this is anticipated to fuel the demand for ocular drug in the region. Moreover, improvements in healthcare infrastructure, launch of various ocular products along with extensive demand for ocular solutions for the treatment of glaucoma and dry eyes, and presence of key market players are the major factors catalyzing the growth of the Ocular Drug Delivery Mode Market in the forthcoming period as stated in MarkNtel Advisors’ research report “Global Ocular Drug Delivery Mode Market Analysis, 2020”.

According to MarkNtel Advisors, the key players with a considerable market share in the Global Ocular Drug Delivery Mode market are Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., Eyegate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc.

Get Sample Report + All Related Graphs & Charts (with COVID 19 Analysis) @ https://www.marknteladvisors.com/query/request-sample/global-ocular-drug-delivery-mode-market.html?utm_source=Openpr&utm_medium=PR

Market Segmentation:
1. By Disease Type (Diabetic Retinopathy, Diabetic Macular Edema, Dry Eye Syndrome, Glaucoma, Macular Degeneration, Cataract, Others)
2. By Technology (Topical Iontophoresis, Ocular Insert [Erodible, Non-Erodible], Intraocular Implants [Biodegradable, Non-Biodegradable], In Situ Gel & Punctal Plugs, Others)
3. By Formulation Type (Liposomes & Nanoparticles, Solution, Emulsion, Suspension, Ointment)
4. By End-user (Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers, Homecare Settings)
5. By Region (North America, South America, Europe, Asia-Pacific, Middle East & Africa)
6. By Country (US, Canada, Brazil, Argentina, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, South East Asia, UAE, Saudi Arabia, Turkey, South Africa),
7. By Company (Valeant Pharmaceuticals International, Inc., Taiwan Liposome Company, Ltd., Ocular Therapeutix, Inc., Graybug Vision Inc., Eyegate Pharma, Clearside Biomedical, Inc., Alimera Sciences, Envisia Therapeutics, Allergan, Plc.)

Key questions answered in the study:
1. What are the current and future trends of the Ocular Drug Delivery Mode industry?
2. How the industry has been evolving in terms of end-user demand and application areas?
3. How the competition has been shaping across the countries followed by their comparative factorial indexing?
4. What are the key growth drivers and challenges for the Ocular Drug Delivery Mode industry?
5. What is the customer orientation, purchase behavior, and expectations from the Ocular Drug Delivery Mode firms across various regions?

MarkNtel Advisors
1147 88AVE, Delta, British Columbia, BC,V4C,3B8, CANADA
Email: updates@markntelgroup.com
Tel: +1613-707-5086
Website: https://www.marknteladvisors.com/?utm_source=Openpr&utm_medium=pr

About MarkNtel Advisors
MarkNtel Advisors is a leading research, consulting and data analytics firm that provides a wide range of strategic reports on diverse industry verticals to a substantial and varied client base that includes multinational corporations, financial institutions, governments, and individuals.

We specialize in niche industries and emerging geographies to support our clients in the formulation of strategies viz. Go to Market (GTM), product development, feasibility analysis, project scoping, market segmentation, competitive benchmarking, market sizing & forecasting, trend analysis, etc. in around 15 industry verticals to enable our clients in identifying attractive investment opportunities and maximizing ROI through an early mover advantage.

This release was published on openPR.